Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

565
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
565
Dementia01:30

Dementia

285
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
285
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
Amyloid Fibrils03:03

Amyloid Fibrils

11.1K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.1K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.0K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Human microglial transitions at the Aβ-tau inflection point associate with divergent pathways to dementia and resilience.

Nature medicine·2026
Same author

Tracking the turning point in Alzheimer's disease.

Science (New York, N.Y.)·2026
Same author

Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ42 fibrils with cross-seeding activity.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Aβ plaques induce local pre-synaptic toxicity in human iPSC-derived neuron xenografts.

Stem cell reports·2026
Same author

The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia.

Nature neuroscience·2025
Same author

Phagocytes as Plaque Catalysts: Human Macrophages Actively Generate Pathogenic Aβ42 Fibrils with Seeding and Cross-Seeding Potency.

bioRxiv : the preprint server for biology·2025

相关实验视频

Updated: Nov 15, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

531

阿尔茨海默病

Philip Scheltens1, Bart De Strooper2, Miia Kivipelto3

  • 1Alzheimer Centre Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands; Department of Neurology, Amsterdam University Medical Centers, Amsterdam, Netherlands; Life Science Partners, Amsterdam, Netherlands.

Lancet (London, England)
|March 5, 2021
PubMed
概括

阿尔茨海默病 (AD) 是一个日益严重的全球性问题, 患病率和遗传联系越来越强. 通过生物标志物及潜在的生活方式干预的早期发现为治疗阿尔茨海默病的进展提供了希望.

更多相关视频

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.5K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.1K

相关实验视频

Last Updated: Nov 15, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

531
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.5K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.1K

科学领域:

  • 神经学
  • 老年学
  • 遗传学

背景情况:

  • 预计到2050年,阿尔茨海默病的发病率将在欧洲增加一倍,在全球增加三倍.
  • 阿尔茨海默病的早期细胞阶段涉及粉样β的积累和tau病理的扩散.
  • 遗传性占阿尔茨海默病风险的60-80%,APOE等位基因是关键的遗传因素.

研究的目的:

  • 总结一下阿尔茨海默病研究的最新进展.
  • 讨论阿尔茨海默病的新兴诊断生物标志物和治疗策略.
  • 突出遗传学和生活方式在阿尔茨海默病的发展和管理中的作用.

主要方法:

  • 对有关阿尔茨海默病的最新文献和研讨会结果的回顾.
  • 对痴呆症患病率的流行病学数据的分析.
  • 检查遗传风险因素,包括APOE等位基因.
  • 对粉样β和化的新生物标志物的评估 (PET扫描,血测定).
  • 在临床试验中评估多领域的生活方式干预和药物治疗.

主要成果:

  • 全球预计痴呆症患病率显著增加.
  • 鉴定了40多个AD遗传风险基因,其中APOE基因具有最强的关联.
  • 对于早期发现和监测阿尔茨海默病的新生物标志物有希望的结果.
  • 证据表明多领域生活方式干预的认知效益.
  • 临床试验中的抗粉样β,抗tau和抗炎药物的进展.

结论:

  • 阿尔茨海默病对公众健康构成重大和日益严重的挑战.
  • 通过先进的生物标志物和潜在的遗传洞察力进行早期检测对于阿尔茨海默病的治疗至关重要.
  • 生活方式干预可能对患有阿尔茨海默病风险的个体的认知健康有好处.
  • 针对关键病理途径的新兴药物治疗对未来的阿尔茨海默病治疗有希望.